共 81 条
[1]
Andrews NJ(2012)Impact and effectiveness of 23-valent pneumococcal polysaccharide vaccine against invasive pneumococcal disease in the elderly in England and Wales Vaccine 30 6802-6808
[2]
Waight PA(2016)The cost-effectiveness of pneumococcal vaccination in healthy adults over 50: an exploration of influential factors for Belgium Vaccine 34 2016-2012
[3]
George RC(2014)Eligibility criteria for publicly funded vaccines/biologics Health Professionals NBIPG 3 3-363
[4]
Blommaert A(2013)Diagnoses and timing of 30-day readmissions after hospitalization for heart failure, acute myocardial infarction, or pneumonia JAMA 309 355-604
[5]
Bilcke J(2015)Ten-year mortality after community-acquired pneumonia: a prospective cohort Am J Respir Crit Care Med 192 597-2111
[6]
Willem L(2000)23-valent pneumococcal polysaccharide vaccine in HIV-1-infected Ugandan adults: double-blind, randomized, and placebo controlled trial Lancet 355 2106-311
[7]
Dharmarajan K(2002)Comparing potential benefits of new pneumococcal vaccines with the current polysaccharide vaccine in the elderly Vaccine 21 303-3584
[8]
Hsieh AF(2015)Economic evaluation of immunisation programme of 23-valent pneumococcal polysaccharide vaccine and the inclusion of 13-valent pneumococcal conjugate vaccine in the list for single-dose subsidy to the elderly in Japan PLoS One 10 e0139140-3593
[9]
Lin Z(2013)Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults Vaccine 31 3577-1348
[10]
Eurich DT(2013)Immunogenicity and safety of a 13-valent pnuemococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine Vaccine 31 3585-1550